Introduction:
A systematic review and meta-analysis of clinical trials was undertaken to evaluate the effect of diacerein intake on
cardiometabolic profiles in patients with type 2 diabetes mellitus (T2DM).
Methods:
Electronic databases such as PubMed, EMBASE, Scopus, Web of Science, Google Scholar, and Cochrane Central Register of
Controlled Trials were searched from inception to 31 July 2019. Statistical heterogeneity was evaluated using Cochran’s Q test and I-square
(I2
) statistic. Data were pooled using random-effect models and weighted mean difference (WMD).
Results:
From 1,733 citations, seven clinical trials were eligible for inclusion and meta-analysis. A significant reduction in hemoglobin A1c (HbA1c)
(WMD -0.73; 95%CI -1.25 to -0.21; P= 0.006; I2
= 72.2%) and body mass index (BMI) (WMD -0.55; 95%CI -1.03 to -0.07; P=
0.026; I2
= 9.5%) were identified. However, no significant effect of diacerein intake was identified on fasting blood sugar (FBS) (WMD -
9.00; 95%CI -22.57 to 4.57; P= 0.194; I2
= 60.5%), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD 0.39; 95%CI
0.95 to 1.73; P= 0.569; I2
= 2.2%), body weight (WMD -0.54; 95%CI -1.10 to 0.02; P= 0.059), triglycerides (WMD -0.56; 95%CI -24.16 to
23.03; P= 0.963; I2
= 0.0%), total-cholesterol (WMD -0.21; 95%CI -12.19 to 11.78; P= 0.973; I2
= 0.0%), HDL-cholesterol (WMD -0.96;
95%CI -2.85 to 0.93; P= 0.321; I2
= 0.0%), and LDL-cholesterol levels (WMD -0.09; 95%CI -8.43 to 8.25; P= 0.983; I2
= 37.8%).
Conclusion:
Diacerein intake may reduce HbA1c and BMI; however, no evidence of effect was observed for FBS, HOMA-IR, body weight,
triglycerides, total-cholesterol, HDL-cholesterol or LDL-cholesterol.
Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis